Edvin Johansson (Senior Imaging Director at Antaros Medical) will be presenting next week at EASL Congress 2024. The presented research, done in collaboration with Uppsala University, assessed gadoxetate-enhanced magnetic resonance imaging (GA-MRI) parameters for measuring fibrosis and inflammation in metabolic dysfunction-associated steatotic liver disease (MASLD).
Chronic liver diseases like MASLD are characterised by decreased hepatic function resulting from inflammation, cholestasis and/or fibrosis. Currently available methods (e.g. liver biopsies) and biomarkers (e.g. plasma biomarkers) for assessing fibrosis and inflammation are limited in their suitability for longitudinal monitoring of therapeutic effects within clinical trials. There is an unmet need for non invasive biomarkers to measure fibrosis and inflammation.
Gadoxetate-enhanced MRI enables quantification of hepatocellular function and can potentially be used to identify dysfunction. This study in biopsy-proven MASLD or metabolic-dysfunction associated steatohepatitis (MASH) evaluated GA-MRI parameters for measuring fibrosis and inflammation. You can read more about how GA-MRI can be used to non-invasively assess liver function here.
Abstract title: Gadoxetic acid-enhanced MRI enables detection of fibrosis and inflammation in MASLD/MASH
Abstract number: 559; WED-316
Authors: Johansson E, Alsaqal S, Hockings P, Ahlström H, Hulthe J, Johansson L, Ebeling Barbier C, Rorsman F, Vessby J
Poster presentation in MASLD: Diagnostics and non-invasive assessment, June 5
The European Association for the Study of the Liver (EASL) Congress will be held from June 5-8 in Milan, Italy, as well as virtually. Find the entire Scientific Programme here.